Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

New PBC drug: Seladelpar

Monday 02 June 2025

We are pleased to announce the addition of the new selective PPARδ agonist, seladelpar (Livdelzi®, Lyvdelzi®) to the hepatology drug interaction checker. Seladelpa is indicated for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid, in adults who are non-responsive to ursodeoxycholic acid alone, or who cannot tolerate ursodeoxycholic acid.


All our Interaction Summary Tables have been updated to include seladelpar, and a downloadable update is available for our mobile apps.


Find the PK Factsheet for seladelpar here.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016